Quick Answer
Jazz Pharmaceuticals plc reported Revenue From Contract With Customer Excluding Assessed Tax of $4.27 billion for the year ending 2025.
- Jazz Pharmaceuticals plc showed an increase of +4.9% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Jazz Pharmaceuticals plc's annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: $394.39 million | Q3 2017: $411.86 million | Q1 2018: $444.61 million | Q2 2018: $500.48 million | Q3 2018: $469.37 million | Q4 2018: $476.46 million | Q1 2019: $508.19 million | Q2 2019: $534.13 million | Q3 2019: $537.70 million | Q4 2019: $581.74 million | Q1 2020: $534.73 million | Q2 2020: $562.44 million | Q3 2020: $600.89 million | Q4 2020: $665.52 million | Q1 2021: $607.58 million | Q2 2021: $751.81 million | Q3 2021: $838.12 million | Q1 2022: $813.72 million | Q2 2022: $932.88 million | Q3 2022: $940.65 million | Q1 2023: $892.81 million | Q2 2023: $957.32 million | Q3 2023: $972.14 million | Q1 2024: $901.98 million | Q2 2024: $1.02 billion | Q3 2024: $1.05 billion | Q1 2025: $897.84 million | Q2 2025: $1.05 billion | Q3 2025: $1.13 billion.
- Over the full 10 years of available data (2016 to 2025), Jazz Pharmaceuticals plc's Revenue From Contract With Customer Excluding Assessed Tax has grown by 186.8%.
- Historical annual values: Fiscal year 2025: $4.27 billion | Fiscal year 2024: $4.07 billion | Fiscal year 2023: $3.83 billion | Fiscal year 2022: $3.66 billion | Fiscal year 2021: $3.09 billion | Fiscal year 2020: $2.36 billion | Fiscal year 2019: $2.16 billion | Fiscal year 2018: $1.89 billion | Fiscal year 2017: $1.62 billion | Fiscal year 2016: $1.49 billion.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: